MRKR — Marker Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.30
+$0.00 (+0.00%)
Marker Therapeutics Inc (MRKR) is a biotechnology company listed on NASDAQ. It is led by Juan F. Vera M.D., based in 2450 Holcombe Blvd, Houston, TX, United States, 77021, with about 5 employees. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Net income was -$10.5M. MRKR currently screens at market cap $25.3M.
Use this MRKR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MRKR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MRKR SEC filings page. Lician reads the product cache first so this HTML stays unique to Marker Therapeutics Inc even when a live quote feed is slow.
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
MRKR Key Statistics
Market Cap
$25.34M
Volume
146,617
Previous Close
$1.50
Day Range
$1.48 – $1.60
EPS
-$1.19
Revenue
$0.00
Net Income
-$10.73M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
MRKR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.73M | -$8.24M | -$29.93M | -$41.88M |
| EPS (Diluted) | -$1.19 | -$0.94 | -$3.58 | -$5.47 |
Total Assets
$22.02M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.19M
Operating Cash Flow
-$10.91M
Free Cash Flow
$0.00
Marker Therapeutics Inc Company Information
- Co-Founder, CEO, President, Treasurer, Secretary & Director
- Juan F. Vera M.D.
- Headquarters
- 2450 Holcombe Blvd, Houston, TX, United States, 77021
- Website
- markertherapeutics.com
- Phone
- 713 400 6400
- IPO / Founded
- 2014-03-25
- Sector
- Healthcare
- Industry
- Biotechnology